Dataset Information

Identification of Sclareol As a Natural Neuroprotective Ca_v 1.3-Antagonist Using Synthetic Parkinson-Mimetic Gene Circuits and Computer-Aided Drug Discovery.

ABSTRACT: Parkinson's disease (PD) results from selective loss of substantia nigra dopaminergic (SNc DA) neurons, and is primarily caused by excessive activity-related Ca²⁺ oscillations. Although L-type voltage-gated calcium channel blockers (CCBs) selectively inhibiting Ca_v 1.3 are considered promising candidates for PD treatment, drug discovery is hampered by the lack of high-throughput screening technologies permitting isoform-specific assessment of Cav-antagonistic activities. Here, a synthetic-biology-inspired drug-discovery platform enables identification of PD-relevant drug candidates. By deflecting Cav-dependent activation of nuclear factor of activated T-cells (NFAT)-signaling to repression of reporter gene translation, they engineered a cell-based assay where reporter

SUBMITTER: Wang H

PROVIDER: S-EPMC8895113 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Identification of Sclareol As a Natural Neuroprotective Ca_v 1.3-Antagonist Using Synthetic Parkinson-Mimetic Gene Circuits and Computer-Aided Drug Discovery.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Identification of Sclareol As a Natural Neuroprotective Cav 1.3-Antagonist Using Synthetic Parkinson-Mimetic Gene Circuits and Computer-Aided Drug Discovery.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Identification of Sclareol As a Natural Neuroprotective Ca_v 1.3-Antagonist Using Synthetic Parkinson-Mimetic Gene Circuits and Computer-Aided Drug Discovery.